AG
RARE icon

Aperio Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Aperio Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$2.32M Buy
16,791
+3,238
+24% +$384K 0.01% 1167
2020
Q3 		$1.11M Buy
13,553
+1,695
+14% +$140K ﹤0.01% 1387
2020
Q2 		$928K Buy
11,858
+2,747
+30% +$182K ﹤0.01% 1450
2020
Q1 		$405K Buy
9,111
+563
+7% +$29.2K ﹤0.01% 1755
2019
Q4 		$365K Sell
8,548
-982
-10% -$40.5K ﹤0.01% 1974
2019
Q3 		$408K Buy
9,530
+400
+4% +$21.7K ﹤0.01% 1869
2019
Q2 		$580K Buy
9,130
+1,608
+21% +$102K ﹤0.01% 1696
2019
Q1 		$522K Buy
7,522
+2,049
+37% +$117K ﹤0.01% 1731
2018
Q4 		$238K Sell
5,473
-123
-2% -$6.72K ﹤0.01% 2058
2018
Q3 		$427K Buy
5,596
+49
+0.9% +$3.99K ﹤0.01% 1849
2018
Q2 		$426K Buy
5,547
+472
+9% +$30.5K ﹤0.01% 1825
2018
Q1 		$259K Sell
5,075
-396
-7% -$19.9K ﹤0.01% 2027
2017
Q4 		$254K Buy
+5,471
New +$268K ﹤0.01% 2036
2017
Q3 		– Sell
-3,851
Closed -$239K – 2230
2017
Q2 		$239K Buy
3,851
+299
+8% +$18K ﹤0.01% 2021
2017
Q1 		$241K Buy
+3,552
New +$271K ﹤0.01% 1944

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Aperio Group's RARE Position: Q4 2020 in Review

Aperio Group increased its Ultragenyx Pharmaceutical (RARE) stake by 24% in Q4 2020, buying an estimated $384K and bringing the position to 16,791 shares worth $2.32M. The position accounts for 0.01% of the portfolio, ranked #1167.

Aperio Group first reported a position in RARE in Q1 2017 and has held it in 15 quarters since. 253 funds tracked by Wall St. Rank hold RARE as of Q4 2020.

  • Aperio Group held 16,791 shares of Ultragenyx Pharmaceutical worth $2.32M as of Q4 2020.
  • Aperio Group bought 3,238 Ultragenyx Pharmaceutical shares in Q4 2020, an estimated $384K.
  • Ultragenyx Pharmaceutical made up 0.01% of Aperio Group's portfolio in Q4 2020, its #1167 holding.
  • Aperio Group first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and has held it in 15 quarters since.
  • 253 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.